Compare Davita Inc (DVA) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Futu Holdings Ltd — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Futu Holdings Ltd trades at $113.52 (market cap $15.25B). The key difference: Futu Holdings Ltd is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.39% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Futu Holdings Ltd for 34 Days on average.
| DVA | FUTU | |
|---|---|---|
Market Cap | $11.29B | $15.25B |
Volume | 582,204 | 812,567 |
Sector | Health | Financials |
52-Week High | $240.96 | $199.04 |
52-Week Low | $103.87 | $89.76 |
Typical Hold Time | 114 Days | 34 Days |
Enterprise Value | $24.01B | $15.59B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
FUTU trades at $113.71, up 3.67% today, with a bearish technical signal but strong fundamentals including a 10.86 P/E ratio and 42.92% net margin. Revenue grew to $22.85B in 2025, and cash flow surged to $31.02B in 2024. Recent news highlights expansion efforts like the Moomoo X partnership and a class action lawsuit deadline.
The outlook is mixed: analysts see a 33.7% upside (Zacks, 2026-09-10), but technicals and legal risks weigh. Investment opportunity lies in valuation and growth; risks include lawsuit uncertainty and competitive pressures. Earnings beat in Q2 2026 supports momentum, but Q1 2026 miss shows volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
